Expanded access, also known as compassionate use, allows patients who are seriously or terminally ill to access investigational treatments such as CGT outside clinical trials once other available options have been exhausted.
Zettler said the primary goal of ISCT's working group is to develop resources to help CGT stakeholders provide access in ways that serve patient interests, as well as preserve the ability to conduct clinical trials and get the safety and effectiveness information that is needed about those therapies. "Right now, is a great time to be thinking about these issues," Zettler said. "Patient interest in access outside of clinical trials is surging."
Watch the video below to learn more.